These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35665579)

  • 1. Corrigendum to 'The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study' [Eur J Heart Fail 2022;24:205-214].
    Eur J Heart Fail; 2022 Aug; 24(8):1453. PubMed ID: 35665579
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
    Rosenkranz S; Channick R; Chin KM; Jenner B; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; McLaughlin VV; Du Roure C; Rubin LJ; Sitbon O; Tapson V; Lang IM
    Eur J Heart Fail; 2022 Jan; 24(1):205-214. PubMed ID: 34806261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
    Galiè N; Gaine S; Channick R; Coghlan JG; Hoeper MM; Lang IM; McLaughlin VV; Lassen C; Rubin LJ; Hsu Schmitz SF; Sitbon O; Tapson VF; Chin KM
    Adv Ther; 2022 Jan; 39(1):796-810. PubMed ID: 34727317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
    Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
    J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
    Beghetti M; Channick RN; Chin KM; Di Scala L; Gaine S; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Galiè N
    Eur J Heart Fail; 2019 Mar; 21(3):352-359. PubMed ID: 30632656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
    Gaine S; Sitbon O; Channick RN; Chin KM; Sauter R; Galiè N; Hoeper MM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Tapson V; Ghofrani HA; Lang I
    Chest; 2021 Jul; 160(1):277-286. PubMed ID: 33545163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world experience of selexipag titration in pulmonary arterial hypertension.
    Cullivan S; Natarajan A; Boyle N; McCormack C; Gaine S; McCullagh B
    Br J Cardiol; 2021; 28(3):32. PubMed ID: 35747707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selexipag for the Treatment of Pulmonary Arterial Hypertension.
    Sitbon O; Channick R; Chin KM; Frey A; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; Preiss R; Rubin LJ; Di Scala L; Tapson V; Adzerikho I; Liu J; Moiseeva O; Zeng X; Simonneau G; McLaughlin VV;
    N Engl J Med; 2015 Dec; 373(26):2522-33. PubMed ID: 26699168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.
    Coghlan JG; Channick R; Chin K; Di Scala L; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin V; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Gaine S
    Am J Cardiovasc Drugs; 2018 Feb; 18(1):37-47. PubMed ID: 29307087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experience with Selexipag to Treat Pulmonary Arterial Hypertension].
    Karelkina EV; Goncharova NS; Simakova MA; Moiseeva OM
    Kardiologiia; 2020 Mar; 60(4):36-42. PubMed ID: 32394855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selexipag for the treatment of pulmonary arterial hypertension.
    Genecand L; Wacker J; Beghetti M; Lador F
    Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study.
    Sitbon O; Chin KM; Channick RN; Benza RL; Di Scala L; Gaine S; Ghofrani HA; Lang IM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Tapson VF; Galiè N; Hoeper MM
    J Heart Lung Transplant; 2020 Apr; 39(4):300-309. PubMed ID: 32061506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
    Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
    Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selexipag for the treatment of pulmonary arterial hypertension.
    Skoro-Sajer N; Lang IM
    Expert Opin Pharmacother; 2014 Feb; 15(3):429-36. PubMed ID: 24392948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of selexipag for the treatment of pulmonary hypertension.
    Panagiotidou E; Boutou A; Pitsiou G
    Expert Opin Pharmacother; 2021 Jan; 22(1):29-36. PubMed ID: 32867545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
    Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
    Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies.
    Ghosh RK; Ball S; Das A; Bandyopadhyay D; Mondal S; Saha D; Gupta A
    J Clin Pharmacol; 2017 May; 57(5):547-557. PubMed ID: 27670133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.
    McLaughlin VV; Hoeper MM; Channick RN; Chin KM; Delcroix M; Gaine S; Ghofrani HA; Jansa P; Lang IM; Mehta S; Pulido T; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A; Tapson VF; Perchenet L; Preiss R; Verweij P; Rubin LJ; Galiè N
    J Am Coll Cardiol; 2018 Feb; 71(7):752-763. PubMed ID: 29447737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
    Bruderer S; Hurst N; Remenova T; Dingemanse J
    Expert Opin Drug Saf; 2017 Jun; 16(6):743-751. PubMed ID: 28494686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological characteristics and clinical study results of Selexipag (Uptravi
    Kuwano K; Kosugi K; Fuchikami C; Funaki S
    Nihon Yakurigaku Zasshi; 2021; 156(3):178-186. PubMed ID: 33952848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.